Top-Rated StocksTop-RatedNASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $97.71 -1.02 (-1.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$97.76 +0.05 (+0.05%) As of 09/12/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About ANI Pharmaceuticals Stock (NASDAQ:ANIP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$97.18▼$99.1050-Day Range$63.35▼$98.7352-Week Range$52.50▼$99.50Volume210,857 shsAverage Volume466,511 shsMarket Capitalization$2.12 billionP/E RatioN/ADividend YieldN/APrice Target$88.25Consensus RatingBuy Company Overview ANI Pharmaceuticals, Inc. is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging. ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care. Alongside its proprietary generics business, ANI provides contract development and manufacturing organization (CDMO) services, leveraging its integrated in-house capabilities in sterile and nonsterile production, analytical testing and regulatory support to meet the needs of pharmaceutical partners. Primarily serving markets in North America, ANI maintains multiple U.S. manufacturing facilities certified for complex sterile and nonsterile operations. The company collaborates with major distributors, retail pharmacies, hospitals and healthcare systems, and continues to invest in process optimization and quality systems to expand its product pipeline and support evolving patient needs.AI Generated. May Contain Errors. Read More ANI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreANIP MarketRank™: ANI Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 216th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingBuy Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Downside RiskANI Pharmaceuticals has a consensus price target of $88.25, representing about 9.7% downside from its current price of $97.71.Amount of Analyst CoverageANI Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth9.07% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 9.07% in the coming year, from $3.86 to $4.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is -126.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is -126.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.57% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 7.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.48 Percentage of Shares Shorted10.57% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 7.27%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.12 News SentimentANI Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for ANI Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 6 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows4 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,382,434.00 in company stock.Percentage Held by Insiders11.10% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIP Stock News HeadlinesANI Pharmaceuticals (NASDAQ:ANIP) Director Antonio Pera Sells 7,292 SharesSeptember 5, 2025 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $229,087.36 in StockAugust 27, 2025 | insidertrades.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.September 13 at 2:00 AM | Brownstone Research (Ad)Krista Davis Sells 1,763 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) StockAugust 26, 2025 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 47,012 SharesAugust 23, 2025 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) Hits New 12-Month High on Analyst UpgradeSeptember 11 at 2:13 AM | americanbankingnews.comANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comGuggenheim Raises ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $114.00September 9, 2025 | americanbankingnews.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $55.28 at the beginning of the year. Since then, ANIP shares have increased by 76.8% and is now trading at $97.71. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its earnings results on Friday, August, 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.38. The firm's quarterly revenue was up 53.2% on a year-over-year basis. Read the conference call transcript. Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' top institutional investors include Global Alpha Capital Management Ltd. (3.98%), Ranger Investment Management L.P. (2.46%), William Blair Investment Management LLC (2.26%) and Geode Capital Management LLC (1.97%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Stephen P Carey, Chad Gassert, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Patrick D Walsh, Krista Davis, Thomas Andrew Rowland, Thomas Haughey, Jeanne Thoma, Antonio R Pera, Renee P Tannenbaum and Matthew J Leonard. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/08/2025Today9/12/2025Next Earnings (Estimated)11/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year Founded1996Price Target and Rating Average Price Target for ANI Pharmaceuticals$88.25 High Price Target$114.00 Low Price Target$77.00 Potential Upside/Downside-9.7%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E Ratio25.31 P/E GrowthN/ANet Income-$18.52 million Net Margins-1.37% Pretax Margin-1.97% Return on Equity25.03% Return on Assets8.00% Debt Debt-to-Equity Ratio1.39 Current Ratio2.54 Quick Ratio1.96 Sales & Book Value Annual Sales$614.38 million Price / Sales3.45 Cash Flow$7.52 per share Price / Cash Flow12.99 Book Value$19.11 per share Price / Book5.11Miscellaneous Outstanding Shares21,700,000Free Float19,291,000Market Cap$2.12 billion OptionableOptionable Beta0.63 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ANIP) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
